TargetBeta
FLT1
fms related receptor tyrosine kinase 1 · also VEGFR1, FLT · V-set domain containing
6 programs in company-led studies act on FLT1, from 6 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 815 running | FLT4, KDR | ChEMBL |
| regorafenibrule | Bayer | phase 4 | 404 running | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | ChEMBL |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 761 running | FGFR1, FGFR2, FGFR3, FGFR4, FLT4, KDR, PDGFRA, PDGFRB | ChEMBL |
| Axitinibrule | Pfizer | phase 3 | 454 running | FLT4, KDR | ChEMBL |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 154 running | AURKB, FLT4, KDR | ChEMBL |
| SAR402663 | Sanofi | phase 2 | 11 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 3 programs
- Neoplasms, 3 programs
- Carcinoma, Hepatocellular, 2 programs
- Carcinoma, Renal Cell, 2 programs
- Macular Degeneration, 2 programs
- Carcinoma, 1 program
- Colorectal Neoplasms, 1 program
- Idiopathic Pulmonary Fibrosis, 1 program
- Lung Diseases, Interstitial, 1 program
- Lymphoma, Non-Hodgkin, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 30, 2026lenvatinib · Eisai · phase 4 · NCT07081633
- Jan 8, 2027Axitinib · Pfizer · phase 3 · NCT06495918
- Feb 28, 2027chiauranib · Chipscreen Biosciences · phase 3 · NCT06492915
- May 18, 2027SAR402663 · Sanofi · phase 2 · NCT06660667
- Sep 30, 2027regorafenib · Bayer · phase 4 · NCT02955940
- Nov 14, 2028nintedanib · Boehringer Ingelheim · phase 4 · NCT07335562
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.